RxDoctor Payments Data

Heather Broyles, DO

Ophthalmology · Austin, TXNPI 1043714280

Payments from drug & device makers

$4,733in general payments, 2019–2025

Across 61 payments — averaging $77.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • AbbVie$1K
  • Alcon$497
  • Glaukos Corporation$322
  • Rxsight Inc$178
  • Harrow Eye, LLC$168
  • plus $388 from 7 others

What the payments were for

  • Consulting fees$2,30049%
  • Food & beverage$2,43351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,733 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$124,001
Medicare patients
208
Services billed
1,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine16$20,933
VevyeCyclosporine19$13,831
XiidraLifitegrast12$11,493
ProlensaBromfenac Sodium26$11,025
Prednisolone Acetate104$5,262
MoxifloxacinMoxifloxacin Hcl97$2,412
ValacyclovirValacyclovir Hcl12$645
Timolol Maleate12$526
Brimonidine Tartrate25$453
Latanoprost29$268
Doxycycline Monohydrate12$196
Tramadol Hcl15$8

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$1,412$20,93316 claims
Harrow Eye, LLCVevye$168$13,83119 claims
Bausch & Lomb Americas Inc.Xiidra$1,769$11,49312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →